Frequently Asked Questions about Nurix Therapeutics, Inc. (NRIX)

Name: Nurix Therapeutics, Inc. (NRIX) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Nurix Therapeutics, Inc. (NRIX) do?

Accepted Answer

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatmen...

Question 2

Is Nurix Therapeutics, Inc. (NRIX) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of NRIX reveals an Altman Z-Score of 3.06 and a Piotroski F-Score of 4/9. These metrics, combined with its 5-year revenue trend ($0.08B most recent), help investors decide if NRIX fits their risk profile.

Question 3

What is the current P/E ratio for NRIX?

Accepted Answer

As of the latest trading session, Nurix Therapeutics, Inc. (NRIX) has a trailing P/E ratio of -5.88.

Question 4

Who is the CEO of Nurix Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Nurix Therapeutics, Inc. is Arthur T. Sands.

Question 5

What was NRIX's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Nurix Therapeutics, Inc. reported annual revenues of $0.08B (2025), $0.05B (2024), $0.08B (2023), $0.04B (2022), $0.03B (2021) respectively.

Question 6

Does NRIX pay a dividend?

Accepted Answer

Nurix Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does NRIX have?

Accepted Answer

In its latest reporting period, Nurix Therapeutics, Inc. generated $-0.26B in Free Cash Flow against a total debt load of $0.06B.

Question 8

What is the Price-to-Book (P/B) ratio of Nurix Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Nurix Therapeutics, Inc. (NRIX) is currently 2.89.

Question 9

What is the Price-to-Sales (P/S) ratio of NRIX?

Accepted Answer

Based on trailing twelve-month data, Nurix Therapeutics, Inc. (NRIX) trades at a Price-to-Sales (P/S) ratio of 16.87.

Question 10

What is Nurix Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Nurix Therapeutics, Inc. (NRIX) has a Return on Equity (ROE) of -57.51%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-11	-249.5M	38M	-14M	-263.5M	-301.4M
2024-11	-172.6M	33.9M	-9.3M	-181.9M	-215.8M
2023-11	-81.4M	33.7M	-8.4M	-89.8M	-123.4M
2022-11	-159.8M	28.1M	-12.2M	-172.1M	-200.2M
2021-11	-84.4M	15.8M	-5.7M	-90M	-105.8M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-11	-249.5M	38M	-14M	-263.5M	-301.4M
2024-11	-172.6M	33.9M	-9.3M	-181.9M	-215.8M
2023-11	-81.4M	33.7M	-8.4M	-89.8M	-123.4M
2022-11	-159.8M	28.1M	-12.2M	-172.1M	-200.2M
2021-11	-84.4M	15.8M	-5.7M	-90M	-105.8M